carmel semaglutide CoolSculpting, Semaglutide, and Weight Loss in Arts & Design District, Carmel, IN Transform your weight loss journey

However, robust clinical trial evidence is lacking, and current NICE guidance does not recommend GLP-1 agonists for treating alcohol use disorder

These results were attributed not just to improved glycemic control, but to anti-inflammatory effects on arterial walls, reduced plaque formation, and enhanced endothelial function

In late March, FDA approved a Clearly, the drugs are still popular

All educational guidance emphasizes safety, regulatory status, and the importance of medically supervised decision-making

For patients without established atherosclerotic CV disease (ASCVD) or chronic kidney disease (CKD) and for whom there is a compelling need to minimize weight gain or promote weight loss, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) guidelines recommend GLP-1RA and sodium-glucose co-transporter-2 inhibitor (SGLT2i) drugs as the preferred second-line treatment option for patients with inadequate glycemic control despite use of metformin [1, 9]